Radiotheranostics Industry Insights: Market Forecast to 2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Is The Radiotheranostics Market Size Likely To Evolve From 2025 Through 2034?

The radiotheranostics market has seen rapid expansion in recent years. Its size is expected to increase from $8.79 billion in 2024 to $10.05 billion in 2025, progressing at a compound annual growth rate (CAGR) of 14.4%. The expansion observed historically can be linked to improvements in nuclear medicine, a rise in cancer occurrences, the evolution of personalized medicine, breakthroughs in radiopharmaceuticals, and obtaining regulatory approvals and adhering to standards.

The radiotheranostics market size is projected to experience swift expansion over the coming years. This market is anticipated to reach $16.87 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 13.8%. Key factors driving this growth during the forecast period include progress in targeted cancer treatments, an increase in oncology research, the growing prevalence of chronic illnesses, and the expanding use of theranostic applications. Significant trends during the forecast period encompass the development of theranostic radiopharmaceuticals, their broader application beyond cancer treatment, the emergence of personalized radiopharmaceuticals, the integration of nanotechnology within radiotheranostics, and evolving regulatory frameworks along with standardization efforts.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12270&type=smp

What Are The Main Drivers Boosting The Radiotheranostics Industry’s Expansion?

The rising occurrence of cancer is projected to fuel the expansion of the radiotheranostics market in the future. Cancer refers to a disease characterized by the uncontrolled proliferation and dissemination of certain cells within the body to other areas. In cancer treatment, radiotheranostics medicines are frequently utilized to embody the concept of personalized medicine. This is achieved through the deployment of combined diagnostic and therapeutic radionuclide probes designed for the targeted and selective identification and treatment of specific cells, predominantly cancer cells. Each application is tailored to the patient’s unique underlying condition, aiming to boost treatment efficacy and achieve superior clinical results. A case in point is the data from January 2024, where the American Cancer Society, a US-based nonprofit cancer advocacy organization, reported a rise in cancer cases to 2,001,140, up from 1,958,310 in 2023, indicating a 2.19% increase. Consequently, the escalating incidence of cancer is a key driver for the radiotheranostics market.

What Are The Major Segments Identified In The Radiotheranostics Market?

The radiotheranosticsmarket covered in this report is segmented –

1) By Radioisotope: Technetium-99; Gallium-68; Iodine-131; Iodine-123; Fludeoxyglucose-18F; Yttrium-90; Lutetium (Lu) 177; Copper (Cu) 67; Copper (Cu) 64; Other Radioisotopes

2) By Approach: Targeted Therapeutic; Targeted Diagnostic

3) By Application: Oncology; Non-Oncology

4) By End-Users: Hospitals And Clinics; Pharmaceutical And Biotechnology Companies; Other End-Users

Subsegments:

1) By Technetium-99: Technetium-99m; Technetium-99 Pertechnetate

2) By Gallium-68: Gallium-68 DOTATATE; Gallium-68 PSMA

3) By Iodine-131: Iodine-131 For Thyroid Cancer Treatment; Iodine-131 For Hyperthyroidism Treatment

4) By Iodine-123: Iodine-123 For Thyroid Scans; Iodine-123 For Cardiac Imaging

5) By Fludeoxyglucose-18F (FDG): FDG For Oncology Imaging; FDG For Brain Imaging

6) By Yttrium-90: Yttrium-90 Microspheres For Liver Cancer; Yttrium-90 For Radioimmunotherapy

7) By Lutetium (Lu) 177: Lutetium-177 PSMA For Prostate Cancer; Lutetium-177 DOTATATE For Neuroendocrine Tumors

8) By Copper (Cu) 67: Copper-67 For Targeted Radiotherapy; Copper-67 In Clinical Trials

9) By Copper (Cu) 64: Copper-64 For PET Imaging; Copper-64 For Radiotherapy

10) By Other Radioisotopes: Radium-223; Samarium-153; Other Emerging Radioisotopes In Theranostics

Which Key Trends Are Expected To Influence The Radiotheranostics Market In The Coming Years?

A prominent trend gaining traction within the radiotheranostics market involves product innovations. Key companies are directing their efforts toward creating inventive products to solidify their position in the market. As an illustration, in May 2023, Advanced Cyclotron Systems Inc., a Canada-based firm that supplies and services cyclotrons primarily used for manufacturing medical isotopes, introduced TR-ALPHA. This system is designed for producing alpha-emitting radioisotopes to combat cancer. It effectively meets the market demand for an economical cyclotron capable of generating significant quantities of Astatine-211, which stands out as one of the most promising alpha-emitting radioisotopes. The TR-ALPHA is also considerably smaller, more affordable, and simpler to operate than previous cyclotron models equipped to produce alpha-emitting radioisotopes. It represents an ideal solution for hospitals, researchers, and institutions aiming to run a dedicated cyclotron for the efficient generation of substantial amounts of therapeutic alpha-emitting radioisotopes.

Which Leading Companies Dominate The Radiotheranostics Market Share?

Major companies operating in the radiotheranostics market include Lantheus Holdings Inc., Cardinal Health Inc., GE Healthcare Inc., Bayer AG, Novartis AG, Siemens Healthineers, Orano Med, Curium SAS, IBA Molecular, The Eckert & Ziegler Group, Advanced Accelerator Applications (AAA), Telix Pharmaceuticals Limited., Abdera Therapeutics, Blue Earth Diagnostics, Sirtex Medical Limited, Y-mAbs Therapeutics Inc., ITM Radiopharma, NorthStar Medical Radioisotopes LLC, Trasis S.A., Molecular Targeting Technologies Inc., RadioMedix Inc, Clarity Pharmaceuticals, Actinium Pharmaceuticals Inc., Navidea Biopharmaceuticals Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/radiotheranostics-global-market-report

How Does The Radiotheranostics Market Perform Across Key Geographic Regions?

North America was the largest region in the radiotheranostics market in 2024. The regions covered in the radiotheranostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Radiotheranostics Market Report:

https://www.thebusinessresearchcompany.com/customise?id=12270&type=smp

Browse Through More Reports Similar to the Global Radiotheranostics Market 2025, By The Business Research Company

Cardiac Assist Devices And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cardiac-assist-devices-and-equipment-global-market-report

White Goods Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/white-goods-global-market-report

Food Service Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/food-service-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795